Friday, 16 October 2026European Markets

ZENOBE GRAMME CERT Stock 12.64% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with ZENOBE GRAMME CERT (ZEN.BR) rising 12.64% to €196.00 on Monday while BEL 20 rose 0.1% to €3,707.77.

ZENOBE GRAMME CERT's last close was €196.00, 12.46% below its 52-week high of €223.90.

About ZENOBE GRAMME CERT

Immo-Zenobe Gramme SA engages in the issuance of real estate certificates in Belgium. Immo-Zenobe Gramme SA is based in Molenbeek-Saint-Jean, Belgium. Immo-Zenobe Gramme SA operates as a subsidiary of KBC Bank NV.

Earnings Per Share

As for profitability, ZENOBE GRAMME CERT has a trailing twelve months EPS of €0.17.

PE Ratio

ZENOBE GRAMME CERT has a trailing twelve months price to earnings ratio of 1152.94. Meaning, the purchaser of the share is investing €1152.94 for every euro of annual earnings.

Volatility

ZENOBE GRAMME CERT's last week, last month's, and last quarter's current intraday variation average was 5.46%, 2.23%, and 5.40%.

ZENOBE GRAMME CERT's highest amplitude of average volatility was 7.18% (last week), 3.54% (last month), and 5.40% (last quarter).

Volume

Today's last reported volume for ZENOBE GRAMME CERT is 27 which is 18.18% below its average volume of 33.

More news about ZENOBE GRAMME CERT (ZEN.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com